多发性骨髓瘤化疗后蛋白C、蛋白S活性检测  

Detection of Protein C and Protein S Activity in Multiple Myeloma Patients After Chemotherapy

作　　者：张付华 刘珍 王英 贺艳霞 

机构地区：[1]山东省东营市第一人民医院,东营257091

出　　处：《血栓与止血学》2017年第3期366-368,共3页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的观察VAD方案及联合沙利度胺治疗多发性骨髓瘤患者的蛋白C、蛋白S活性变化及临床意义。方法选取2012年2月至2016年2月我院就诊的108例多发性骨髓瘤患者,随机分为VAD治疗组(56例)和T-VAD治疗组(52例)两组。分别给予VAD化疗方案及T-VAD方案治疗,检测两组的蛋白C和蛋白S活性变化,观察血栓发病情况。结果 2个治疗组均导致蛋白C和蛋白S活性降低,治疗后6月T-VAD组比VAD治疗组降低更明显,T-VAD组治疗后6个月发生静脉血栓率约为VAD治疗组的3倍。结论 VAD化疗方案用于多发性骨髓瘤如联合沙利度胺蛋白C和蛋白S活性降低,静脉血栓发病率升高,蛋白C、蛋白S活性检测可作为应用抗凝治疗的重要参考指标。Objective Observation of VAD chemotherapy and combined with thalidomide in the treatment of patients with multiple myeloma protein C, protein S activity and thrombosis incidence. Methods Selected from February 2011 to February 2015 in our hospital 108 cases of multiple myeloma patients ,random divided into VAD treatment group（56 cases）and T-VAD treatment group （52 cases）two groups. The changes of protein C and protein S activity in the two groups were detected by VAD chemotherapy and T-VAD treatment, respectively, and the incidence of thrombosis was observed. Results The 2 treatment groups were induced protein C and protein S activity decreased, T-VAD group than VAD treatment group decreased more significantly after 6 months treatment, and the incidence of venous thrombosis in group T- VAD was 3 times that of VAD treatment group in 6 months. Conclusion Protein C and Protein S activity decreased in multiple myeloma treated with VAD chemotherapy if added thalidomid, the incidence of venous thrombosis rate increased, the detection of protein C and protein S activity can be used as an important reference to application of anticoagulant therapy.

关 键 词：蛋白C 蛋白S 多发性骨髓瘤 静脉血栓 

分 类 号：R551.3[医药卫生—血液循环系统疾病]